1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models

BACKGROUND: AZD7442—a combination of 2 human, extended–half-life, SARS-CoV-2–neutralizing monoclonal antibodies (mAbs) (tixagevimab/cilgavimab)—has received US Food and Drug Administration emergency use authorization for COVID-19 prevention in immunocompromised individuals. We evaluated the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Loo, Yueh-Ming, Herbert, Andrew S, Kuehne, Ana I, McTamney, Patrick M, Roque, Richard, Moreau, Alicia M, Bakken, Russell, Stefan, Christopher P, Koehler, Jeffrey W, Delp, Korey L, Coyne, Susan R, Kane, Christopher D, Dye, John M, Cai, Yingyun, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752730/
http://dx.doi.org/10.1093/ofid/ofac492.981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752730/
http://dx.doi.org/10.1093/ofid/ofac492.981

Ejemplares similares